ALX Oncology Files 8-K: Director Changes and Officer Appointments
Ticker: ALXO · Form: 8-K · Filed: Sep 12, 2025 · CIK: 1810182
Sentiment: neutral
Topics: management-change, corporate-governance, filing
Related Tickers: ALXO
TL;DR
ALXO leadership shakeup: new directors elected, officers appointed, and compensation details disclosed.
AI Summary
ALX Oncology Holdings Inc. filed an 8-K on September 11, 2025, reporting on the departure of directors, election of directors, appointment of officers, and compensatory arrangements. The filing also covers other events and financial statements/exhibits.
Why It Matters
This filing indicates potential shifts in the company's leadership and governance structure, which could impact strategic direction and operational oversight.
Risk Assessment
Risk Level: medium — Changes in board composition and executive appointments can signal strategic shifts or internal adjustments that may affect future performance.
Key Players & Entities
- ALX Oncology Holdings Inc. (company) — Registrant
- September 11, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 323 Allerton Avenue, South San Francisco, California 94080 (address) — Principal Executive Offices
FAQ
Who has departed from the board of directors or as an officer of ALX Oncology Holdings Inc.?
The filing indicates the departure of directors or certain officers, but specific names are not detailed in the provided text.
Were any new directors elected to the board of ALX Oncology Holdings Inc.?
Yes, the filing explicitly lists 'Election of Directors' as an item of information reported.
Were there any appointments of new officers at ALX Oncology Holdings Inc.?
Yes, the filing states 'Appointment of Certain Officers' as a reported item.
What is the primary business of ALX Oncology Holdings Inc.?
ALX Oncology Holdings Inc. is in the 'Pharmaceutical Preparations' industry, SIC code 2834.
What is the filing date and the earliest event date for this 8-K?
The filing date is September 12, 2025, and the earliest event reported is September 11, 2025.
Filing Stats: 1,043 words · 4 min read · ~3 pages · Grade level 10.4 · Accepted 2025-09-12 08:32:27
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share ALXO The Nasdaq Global Se
- $1.00 — Company's common stock must be at least $1.00 per share for a minimum of ten consecut
Filing Documents
- alxo-20250911.htm (8-K) — 63KB
- alxo-ex99_1.htm (EX-99.1) — 19KB
- img62044099_0.jpg (GRAPHIC) — 146KB
- 0001810182-25-000006.txt ( ) — 392KB
- alxo-20250911.xsd (EX-101.SCH) — 25KB
- alxo-20250911_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. Nasdaq Minimum Bid Price Compliance On September 4, 2025, the Company notified The Nasdaq Stock Market LLC ("Nasdaq") that the Company had regained compliance with the minimum bid price requirement under the Nasdaq Listing Rules which requires that the closing price per share of the Company's common stock must be at least $1.00 per share for a minimum of ten consecutive business days, as described in the Form 8-K filed on April 25, 2025. For the ten consecutive business days, from August 21 through September 4, 2025, the closing bid price of the Company's common stock had been at $1.00 per share or greater. Management Updates On September 11, 2025, Alan Sandler, M.D., informed the Company of his resignation as Chief Medical Officer of the Company, effective September 26, 2025, in order to pursue other professional opportunities. As noted above, Dr. Sandler will return to his role as a director of the Company and remain heavily involved with the Company following his transition. In connection with Dr. Sandler's resignation and to facilitate an orderly transition, effective September 17, 2025, Barbara Klencke, M.D., will assume the role of consulting interim Chief Medical Officer of the Company pursuant to a customary consulting agreement on a full-time basis. Board Governance Updates In connection with the Board and management changes referenced above, the Board approved the following composition of committees of the Board: Audit Committee Rekha Hemrajani, Chair; Daniel Curran, M.D.; and Scott Garland Compensation Committee Corey Goodman, Ph.D., Chair; Scott Garland; and Chris Takimoto, M.D., Ph.D., F.A.C.P. Corporate Governance and Nominating Committee Scott Garland, Chair; Daniel Curran, M.D.; and Rekha Hemrajani The Board also determined to pause the activities of the Research and Development Committee until further determination. In appointing Dr. Curran to the Audit Committee, the Board determined that Dr. Curr
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release dated September 12, 2025. 104 Cover Page Interactive Data File (formatted as Inline XBRL)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ALX ONCOLOGY HOLDINGS INC. Date: September 12, 2025 By: /s/ Harish Shantharam Harish Shantharam Chief Financial Officer